Literature DB >> 35737257

Classification models and SAR analysis on HDAC1 inhibitors using machine learning methods.

Rourou Li1, Yujia Tian1, Zhenwu Yang1, Yueshan Ji1, Jiaqi Ding2, Aixia Yan3.   

Abstract

Histone deacetylase (HDAC) 1, a member of the histone deacetylases family, plays a pivotal role in various tumors. In this study, we collected 7313 human HDAC1 inhibitors with bioactivities to form a dataset. Then, the dataset was divided into a training set and a test set using two splitting methods: (1) Kohonen's self-organizing map and (2) random splitting. The molecular structures were represented by MACCS fingerprints, RDKit fingerprints, topological torsions fingerprints and ECFP4 fingerprints. A total of 80 classification models were built by using five machine learning methods, including decision tree (DT), random forest, support vector machine, eXtreme Gradient Boosting and deep neural network. Model 15A_2 built by the XGBoost algorithm based on ECFP4 fingerprints showed the best performance, with an accuracy of 88.08% and an MCC value of 0.76 on the test set. Finally, we clustered the 7313 HDAC1 inhibitors into 31 subsets, and the substructural features in each subset were investigated. Moreover, using DT algorithm we analyzed the structure-activity relationship of HDAC1 inhibitors. It may conclude that some substructures have a significant effect on high activity, such as N-(2-amino-phenyl)-benzamide, benzimidazole, AR-42 analogues, hydroxamic acid with a middle chain alkyl and 4-aryl imidazole with a midchain of alkyl whose α carbon is chiral.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Classification models; Histone deacetylase (HDAC) 1 inhibitor; Machine learning method; Structure clustering; Structure–activity relationship (SAR)

Year:  2022        PMID: 35737257     DOI: 10.1007/s11030-022-10466-w

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  38 in total

Review 1.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.

Authors:  X-J Yang; E Seto
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

2.  Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.

Authors:  Eftiola Pojani; Daniela Barlocco
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

3.  Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

Authors:  Zhenhuan Zhang; Hiroko Yamashita; Tatsuya Toyama; Hiroshi Sugiura; Yoshiaki Ando; Keiko Mita; Maho Hamaguchi; Yasuo Hara; Shunzo Kobayashi; Hirotaka Iwase
Journal:  Breast Cancer Res Treat       Date:  2005-11       Impact factor: 4.872

Review 4.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

5.  Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.

Authors:  Bo Zhang; Yan Wang; Xueli Pang
Journal:  Med Oncol       Date:  2010-05-13       Impact factor: 3.064

6.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

Authors:  Ivan V Gregoretti; Yun-Mi Lee; Holly V Goodson
Journal:  J Mol Biol       Date:  2004-04-16       Impact factor: 5.469

Review 7.  Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.

Authors:  Madeleine Duvic; Jenny Vu
Journal:  Expert Opin Investig Drugs       Date:  2007-07       Impact factor: 6.206

8.  Inhibition of bladder tumour growth by histone deacetylase inhibitor.

Authors:  Akira Ozawa; Nozomu Tanji; Tadahiko Kikugawa; Toyokazu Sasaki; Yutaka Yanagihara; Noriyoshi Miura; Masayoshi Yokoyama
Journal:  BJU Int       Date:  2009-08-13       Impact factor: 5.588

9.  Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

Authors:  Kalipso Halkidou; Luke Gaughan; Susan Cook; Hing Y Leung; David E Neal; Craig N Robson
Journal:  Prostate       Date:  2004-05-01       Impact factor: 4.104

Review 10.  Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors.

Authors:  Ligong Liu; Lilong Dong; Erika Bourguet; David P Fairlie
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.